Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic

Thrombosis and Haemostasis

Volumn 96, Issue 2, 2006, Pages 137-141

  Wittkowsky, Ann K ^a   Downing, Jennifer ^a   Blackburn, Juan ^b   Nutescu, Edith ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulation clinic; Antiphospholipid antibody syndrome; Thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL EXAMINATION; CLINICAL OBSERVATION; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG INDICATION; EMERGENCY WARD; FEMALE; HEALTH CARE FACILITY; HEALTH CARE UTILIZATION; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SEX DIFFERENCE; STROKE; SUBDURAL HEMATOMA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; COHORT STUDIES; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 33747102710     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-02-0090     Document Type: Article

References (18)

1. Levine JS, Branch R, Rauch J. The antiphospholipid syndrome. New Engl J Med 2002; 346: 752-63.
2. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
3. Albers GW, Amarenco J, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 483s-512s
4. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401s-428s.
5. Krnic-Barrie S, O'Connor CR, Looney SW, et al. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101-8.
6. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thromboembolic event in 70 patients. Ann Intern Med 1992; 117: 303-8.
7. Ruiz-Irastorza G, Shamashta MA, Hunt BJ, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Analysis of a series of 66 patients treated with oral anticoagulation to a target International Normalized Ratio of 3.5. Arch Intern Med 2002; 162: 1164-9.
8. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332:993-7.
9. Ansell J. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management. Semin Vasc Med 2003; 3: 261-70.
10. Chiquette E, Amato M, Bussey H. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7.
11. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005; 127: 1515-22.
12. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004; 24: 1311-6.
13. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N EngI J Med 2003; 349: 1133-8.
14. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin versus conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
15. Moll S, Oertel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997; 127: 177-85.
16. Rosborough TK, Shepard ME. Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 2004; 24: 838-42.
17. Dentali F, Manfredi E, Crowther M, et al. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005; 3: 2121-3.
18. Rouby RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003; 48: 3004-8.